Currently, EGFR tyrosine kinase inhibitors (EGFR-TKIs) are recommended by clinical guidelines as first-line therapeutic drugs [6–8] for advanced NSCLC patients with EGFR-sensitive mutations and no resistance genes. This evidence concerns the gene EGFR and non-small cell lung carcinoma.